MecaserminMeSH Supplementary Concept

https://ansm.sante.fr/tableau-marr/mecasermine
2024
false
false
false
France
French
risk management
mecasermin
mecasermin
mecasermin
Drug-Related side effects and adverse reactions
patient education handout
guidelines for drug use
mecasermin
hypoglycemia
injections, subcutaneous

---
https://www.has-sante.fr/jcms/p_3193753/fr/increlex
2020
false
false
false
France
mecasermin
insurance, health, reimbursement
child
adolescent
failure to thrive
insulin-like growth factor i
Growth delay due to insulin-like growth factor type 1 deficiency (disorder)
evaluation of the transparency committee
mecasermin
insulin-like growth factor i
recombinant proteins
insulin-like growth factor i
recombinant proteins

---
https://www.ansm.sante.fr/actualites/mecasermine-increlex-et-risque-de-tumeur-benigne-ou-maligne-extension-de-la-contre-indication
2020
false
false
false
France
French
neoplasms
mecasermin
mecasermin
mecasermin
child
adolescent
failure to thrive
pharmacovigilance note
insulin-like growth factor i
guidelines for drug use
insulin-like growth factor i
recombinant proteins
insulin-like growth factor i
recombinant proteins

---
https://ansm.sante.fr/uploads/2020/03/05/85b70141e0ccefd2207b2892e56bb885.pdf
2020
false
false
false
France
French
neoplasms
risk
mecasermin
pharmacovigilance note
child
adolescent
mecasermin
insulin-like growth factor i
failure to thrive
mecasermin
mecasermin
insulin-like growth factor i
recombinant proteins
insulin-like growth factor i
recombinant proteins
insulin-like growth factor i
recombinant proteins

---
https://www.has-sante.fr/portail/jcms/c_2761840/fr/increlex
https://www.has-sante.fr/portail/jcms/c_2761840/fr/increlex-mecasermine-somatropine
2017
false
France
French
evaluation of the transparency committee
mecasermin
mecasermin
guidelines for drug use
insulin-like growth factor i
insulin-like growth factor i
treatment outcome
mecasermin
orphan drug production
insulin-like growth factor i
child
adolescent
injections, subcutaneous
failure to thrive
insurance, health, reimbursement

---
http://www.cochrane.org/fr/CD002064
2012
false
France
United Kingdom
French
french abstract
meta-analysis
amyotrophic lateral sclerosis
treatment outcome
insulin-like growth factor i
intercellular signaling peptides and proteins
mecasermin

---
https://www.ema.europa.eu/medicines/human/EPAR/Increlex
2012
false
United Kingdom
English
French
syndication feed
mecasermin
mecasermin
insulin-like growth factor i
failure to thrive
child
adolescent
injections, subcutaneous
treatment outcome
orphan drug production
drug interactions
pregnancy
breast feeding
drug storage
drug approval
drug labeling
Drug-Related side effects and adverse reactions
drug evaluation, preclinical
mecasermin
package leaflet
drug evaluation
summary of product characteristics
insulin-like growth factor i
insulin-like growth factor i

---
http://www.has-sante.fr/portail/jcms/c_1121530/increlex-mecasermine-facteur-de-croissance-insulinomimetique-synthese-d-avis
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
mecasermin
mecasermin
treatment outcome
orphan drug production
insurance, health, reimbursement
child
adolescent
insulin-like growth factor i
injections, subcutaneous
failure to thrive
insulin-like growth factor i

---
http://www.has-sante.fr/portail/jcms/c_1080273/increlex
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-08/increlex_-_ct-8906.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/increlex_ct_8906.pdf
2011
false
France
French
English
evaluation of the transparency committee
mecasermin
mecasermin
treatment outcome
mecasermin
orphan drug production
insulin-like growth factor i
child
adolescent
injections, subcutaneous
failure to thrive
insurance, health, reimbursement
insulin-like growth factor i
insulin-like growth factor i

---
http://www.meddispar.fr/medicaments/3814677
2008
false
France
French
mecasermin
drug prescriptions
continuity of patient care
legislation, drug
injections
mecasermin
drug information
insulin-like growth factor i

---